Brian Frawley is a partner in Sullivan & Cromwell’s Litigation Group. His practice focuses on a broad range of complex securities, derivative and commercial litigation, as well as the defense of significant regulatory matters.
Mr. Frawley regularly counsels clients in litigation arising out of mergers and acquisitions, including recent transactions involving Anheuser-Busch InBev, AT&T, Bayer, Columbia Pipeline, Cytec Industries, DISH Networks, Forest City Realty, KCG Holdings, Merck KGaA, NorthStar Asset Management, Novartis, Seattle Genetics, Solera Holdings, Sotheby’s, Tiffany, and Tokio Marine, among others. He also frequently represents financial advisors in disputes arising out of mergers or acquisitions, including Barclays, Centerview, Houlihan Lokey, and Lazard, among others.
Mr. Frawley is the co-coordinator of the Firm’s mergers and acquisition litigation practice, and the co-author of “Derivative Actions by Stockholders,” in 4 Business and Commercial Litigation in Federal Courts, Chapter 20.
He also represents corporations and individuals at trial and on appeal in a wide variety of complex business and securities litigation in state and federal courts throughout the country, before arbitration panels, and in investigations and proceedings involving state and federal regulators. Mr. Frawley has represented corporations and individuals in some of the most important federal securities litigations in the country. He regularly advises senior executives and boards of directors on significant litigation and regulatory matters.
